PH-762 use does not involve genetic engineering, and its cell delivery does not require special formulations or other complex delivery tools.
https://www.google.com/url?rct=j&sa=t&url=https://www.prnewswire.com/news-releases/phio-pharmaceuticals-and-agonox-inc-announce-collaboration-on-clinical-development-of-novel-t-cell-based-cancer-immunotherapies-301237317.html&ct=ga&cd=CAIyGjg0YzkwMzEwZTQwYzQxNjA6Y29tOmVuOlVT&usg=AFQjCNEZDlVJBYb-_2Ed8tlx-B2U1UQwtA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.